Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A few more days at 15 cents will confirm. Sure hope that is the case because the Benzinga article should give us a nice boost if before IDE OR it will add fuel to the rocket after IDE is submitted.
🤞🙏🚀💣💥🍾🤑🍾🍺🎊🍾
Highly doubt it. Would be awesome if it did happen.
Would be so nice...🤞🙏
I hope you are right. We will see in a few months.
If my post has bad information, then someone who has good information should refute my post, as you did.
You didn't get into specifics, I notice...how many shares out of the 22.94M shares that were sold were Reg A??
The reason for discussion boards is to share information and ideas, even feelings and predictions on the future of the company and share price. The deleting of a post due to it containing bad information is akin to cutting someone's tongue out for saying something you don't agree with. THAT is the wrong answer!
This a great summary of the dilution since 4Aug23: 22,946,208 shares @ $0.08 = $1.835M. The price drop you see now (imo) is in large part due to dilution with other factors at play. I repeatedly criticized management for the focus on IsoPet (expansion of vet clinics and attendance of vet conferences) because it generates no revenue and costs lots of money. I was criticized heavily every time I made that point. Many on this board tried to say that IsoPet was providing critical data for IDE application, but that simply isn't true. Expansion of vet clinics and attending vet conferences did NOTHING to generate any data, only the required rabbit tests and possibly the genotoxicity tests provided data and that was required and therefore good.
Everyone who criticized me for complaining about the focus on IsoPet apparently forgets that I told the board, numerous times, that focus on IsoPet would needlessly use more money and that would drive the company to need to sell more shares. All of this has happened, and now those very people that complained about my posts are now complaining about the drop in share price...you can't make this up!!!
This price drop could continue for weeks depending on how many shares those holders drop into the market and when...throw in the flippers and you have what we see now. It isn't like I didn't warn everyone repeatedly and now everyone can see the results of all the money spent on vet clinic expansion.
What is really weird is that my posts keep getting deleted...that is ok. I am now on my laptop and will report this to iHub authorities if it happens again. Plus, I am going to copy/paste this into a Word doc so I can copy/paste back into here until they leave it. This post is on point and there is ZERO reason to remove it!!!!
That would be foolish. If the IDE is ready, they should submit ASAP. The new investors will absob the new shares within a day or so and price will shoot up more than when they announced Q2 submission.
No manipulation right now Tiger...only dilution.
Actually, we do know it. Dilution is the primary reason, other factors at play as well, but those are all secondary to dilution.
I would NEVER welcome a reverse split. Others here have been through one, yes, but those people also bought those orinal pre-split shares at a much lower cost.
Let's see how this plays out. 1st thing is first, IDE submission and approval.
A reverse split is a terrible thing. We should be able to get to $3+ after 1st successful clinical trial.
We did have 1.5 million shares traded today. Dilution is likely a major component of this continued drop in price, in my opinion. We don't know how long those shares will be dumped before they are done getting rid of them all.
They ran out of money, they had to do it. This isn't a popular opinion, but they could have saved a lot of money by staying focused on IDE but they just had to attend vet seminars and open new vet clinics. All of that cost money....
All OBE now and we should be good thru IDE approval and hopefully 1 clinical trial. After a successful clinical trial, we should see a major move upward in share price which will allow RDGL to sell fewer shares and raise more money.
🤞 we submit IDE by end of June and get approval!!!
They will need to raise additional cash to complete the human trials, but since the IDE will already be approved at that point, they can sell fewer shares at a higher price to meet their expected capital requirement.
I don't see that this will rip. Not with current market sentiment
Was that for me? Cannot tell
I'll do what ever I want. And since I now have 306,000 shares, I'll be in this until they send in the IDE. If approved, I'll stay until they get approval for human use.
Not sorry
A company that says it will do X by this date, and misses that date, might also miss the timeline they set for Y...dipstick.
It demonstrates they don't have a good understanding of schedules. And so far, this company has been terrible about meeting timelines THEY put out publicly.
Dilution, even necessary and minimal, is painful. Case in point is our current downward trajectory due to dilution.
This is why I have been so frustrated with the company focusing so much on IsoPet which costs $$ we don't have and generates zero revenue. It would be much different if every pet clinic brought on board got us $100k/yr., but that isn't the case.
What makes me nervous is missing the Benzinga article publication timeline. If they were wrong about that (can't meet the original date) then are they going to be wrong about IDE submission?
I'm honestly very nervous about that.
For the record I saw this post, looked at the post Tiger responded to, and replied to that post. Funny thing is I had replied to the OP and basically said the same thing I said today.
I will not reply on this topic further...u guys all get so butt hurt. Gheeze
Lol. 99% of my posts are from my phone and I don't dig into historical posts while using it. Again, I was replying to something from today, or thought I was.
I didn't go back that far purposefully, I replied to something from today...not sure how that happened.
Agree with everything you say up to the point where you think RDGL needs to get more aggressive with IsoPet. To me, it is clear as day, there would have been less errors had they focused more on IDE and less in IsoPet; not to mention IsoPet generates $0 for RDGL (unless you count the chump change it generated last year, which I do not).
For shareholders that care about making money, IDE submission is the ONLY way forward. Mark these words: if RDGL doesn't submit the IDE by the end of June, the share price will crash. Also, if the VX2 report information (plus all other required data requested by the FDA) isn't included in the IDE submission and the IDE gets rejected - the share price will crash.
EVERYTHING is dependent on IDE submission and approval. I think they should have had a final meeting with the FDA to ensure they don't need further tests since they didn't tell us coming out of the last meeting with the FDA that it was the last one and the FDA told them they just needed to finalize this last round of tests and then submit.
Time will tell how this plays out. Hopefully RDGL can meet the Q2 submission timeline they keep saying they will make but just like many other things here, they have a habit of missing the deadlines they put out. Case in point - the Benzinga article.
IDE submission in June, likely mid-late June. Also, they might be holding off on Benzinga article until we submit the IDE. Couple of thoughts
Let's see how this week goes. Hope you are right.
I don't deny that the pet side of the business has helped prove the science works. Just disagree on level of effort spent over last 2 years in particular on IsoPet.
Regardless, we can all see the light at the end of the tunnel, and we are all excited to have IDE coming up soon.
If we keep dropping next week I have dry powder and will buy more.
Who said rush? You. I'll repeat slowly: had the company been 100% focused on IDE instead of what seems to be more than 50% of their time and effort over last 2 years focused on IsoPet, I am saying this last round of dilution wouldn't have been necessary. Why? Because the testing would have been started sooner and finished sooner. They have minimal staffing, which is good, but it hurts them when they try to push 2 divisions forward at the same time.
I will use this as an opportunity to buy more shares, but I would MUCH rather have our price at 20 cents + and the testing and analysis done months ago. Who knows how much higher the price would be now if they were focused on what matters most (IDE).
It is what it is...
No need to. I'll see if we keep dropping next week...I'll try to buy more at the low point
Bingo lol! Dilution is one of the primary reasons why I was so frustrated with the company taking 2 years to complete the requirements the FDA gave RDGL. They ran out of money and had to sell more shares, and these higher volume, lower priced days of trading are the result.
Not the end of the world, but had we finished the testing and submitted already, share price would be much much higher.
Hopefully, RDGL can set up the next round of fundraising at $1, the higher the better.
Price movement on such low volume tells me a couple things:
1. Nobody is selling (essentially)
2. Price movements on low volume don't mean much
Remember we got here on high volume (million +) shares traded in a day over weeks.
If you have dry powder, buy more. I know I am just waiting for a nice dip, but it could be our new floor is in the 16-17 cent range.
Konshe you keep making predictions, you keep being so wrong lol.
Next big jump comes from the next positive announcement regarding IDE submission.
I complained a lot over the last 2 years as I didn't like the dilution, some of which in my mind could have been avoided if there was more focus on IDE instead of IsoPet (this last round of selling shares especially)...but overall I have to agree with you. Our CEO has done a great job of getting us here.
I am VERY excited for our future as shareholders and cancer patients.
100%! It has been a tough road to hold long and we all deserve our payday.
Agree - after approval is most likely.
Share structure comes into play on the big boards. If we want major institutional investors ( and we should all want that), then yes, it matters because they all have rules that say they cannot invest in companies that are not on a big board.
Lol